EVEROLIMUS PHARMAZAC 2.5mg tablets
everolimus Indicated for: cancer; post-transplant immunosuppression
letter E · page 53
everolimus Indicated for: cancer; post-transplant immunosuppression
everolimus Indicated for: cancer; post-transplant immunosuppression
everolimus Indicated for: cancer; post-transplant immunosuppression
everolimus Indicated for: cancer; post-transplant immunosuppression
everolimus Indicated for: cancer; post-transplant immunosuppression
everolimus Indicated for: cancer; post-transplant immunosuppression
everolimus Indicated for: cancer; post-transplant immunosuppression
everolimus Indicated for: cancer; post-transplant immunosuppression
everolimus Indicated for: cancer; post-transplant immunosuppression
rivastigmine Indicated for: Alzheimer's disease; dementia
N06DA03 Nervous system | Anti-dementia drugs | Anticholinesterases
rivastigmine Indicated for: Alzheimer's disease; dementia
N06DA03 Nervous system | Anti-dementia drugs | Anticholinesterases
rivastigmine Indicated for: Alzheimer's disease; dementia
N06DA03 Nervous system | Anti-dementia drugs | Anticholinesterases
rivastigmine Indicated for: Alzheimer's disease; dementia
N06DA03 Nervous system | Anti-dementia drugs | Anticholinesterases
rivastigmine Indicated for: Alzheimer's disease; dementia
N06DA03 Nervous system | Anti-dementia drugs | Anticholinesterases
rivastigmine Indicated for: Alzheimer's disease; dementia
N06DA03 Nervous system | Anti-dementia drugs | Anticholinesterases
estradiol + norethisterone Indicated for: menopausal symptoms
raloxifene Indicated for: osteoporosis
evinacumab Indicated for: dyslipidemia
levofloxacin Indicated for: bacterial infections
J01MA12 Antiinfectives for systemic use | Quinolone antibacterials | Fluoroquinolones
clofarabine Indicated for: leukemia
L01BB06 Antineoplastic and immunomodulating agents | Antimetabolites | Purine analogues